OTCMKTS:PBSV Pharma-Bio Serv (PBSV) Stock Price, News & Analysis $0.48 -0.02 (-4.00%) As of 06/4/2025 12:54 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendEarningsSEC FilingsShort InterestBuy This Stock About Pharma-Bio Serv Stock (OTCMKTS:PBSV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pharma-Bio Serv alerts:Sign Up Key Stats Today's Range$0.47▼$0.5050-Day Range$0.43▼$0.5952-Week Range$0.31▼$0.70Volume2,730 shsAverage Volume8,782 shsMarket Capitalization$11.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.Read More… Pharma-Bio Serv Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScorePBSV MarketRank™: Pharma-Bio Serv scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pharma-Bio Serv. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharma-Bio Serv is -16.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharma-Bio Serv is -16.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPharma-Bio Serv has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pharma-Bio Serv's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Pharma-Bio Serv has been sold short.Short Interest Ratio / Days to CoverPharma-Bio Serv has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthWeak Dividend YieldPharma-Bio Serv does not currently pay a dividend.Dividend GrowthPharma-Bio Serv does not have a long track record of dividend growth.Read more about Pharma-Bio Serv's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the float of Pharma-Bio Serv has been sold short.Short Interest Ratio / Days to CoverPharma-Bio Serv has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Pharma-Bio Serv this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pharma-Bio Serv insiders have not sold or bought any company stock.Percentage Held by Insiders12.20% of the stock of Pharma-Bio Serv is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Pharma-Bio Serv's insider trading history. Receive PBSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharma-Bio Serv and its competitors with MarketBeat's FREE daily newsletter. Email Address PBSV Stock News HeadlinesPharma-Bio Serv (PBSV) Projected to Post Quarterly Earnings on FridayJune 6 at 1:20 AM | americanbankingnews.comPBSV Returns to GrowthMarch 18, 2025 | msn.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.June 6, 2025 | Brownstone Research (Ad)Pharma-Bio Serv Inc.: Pharma-Bio Serv Announces Full Year ResultsJanuary 31, 2025 | finanznachrichten.dePBSV Released Earnings and Declares DividendJanuary 30, 2025 | msn.comPharma-Bio Serv declares special dividend for shareholdersJanuary 30, 2025 | msn.comScotiabank Initiates Coverage of BridgeBio Pharma (BBIO) with Sector Outperform RecommendationOctober 17, 2024 | msn.comBristol Myers, 2seventy bio halt enrollment in Abecma late-stage trialSeptember 25, 2024 | msn.comSee More Headlines PBSV Stock Analysis - Frequently Asked Questions How have PBSV shares performed this year? Pharma-Bio Serv's stock was trading at $0.5499 at the start of the year. Since then, PBSV stock has decreased by 12.7% and is now trading at $0.48. View the best growth stocks for 2025 here. How were Pharma-Bio Serv's earnings last quarter? Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) released its quarterly earnings data on Monday, March, 17th. The company reported $0.37 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.35. The business had revenue of $2.47 million for the quarter, compared to the consensus estimate of $2.70 million. Pharma-Bio Serv had a negative net margin of 8.18% and a negative trailing twelve-month return on equity of 5.61%. How do I buy shares of Pharma-Bio Serv? Shares of PBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pharma-Bio Serv own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharma-Bio Serv investors own include AT&T (T), Annaly Capital Management (NLY), BlackRock Multi-Sector Income Trust (BIT), GE Aerospace (GE), Exxon Mobil (XOM), Enterprise Products Partners (EPD) and First BanCorp. (FBP). Company Calendar Record date for 3/20 Dividend2/28/2025Ex-Dividend for 3/20 Dividend2/28/2025Last Earnings3/17/2025Dividend Payable3/20/2025Today6/06/2025Next Earnings (Estimated)6/13/2025Fiscal Year End10/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorBusiness Services Industry Management consulting services Sub-IndustryBusiness Services Current SymbolOTCMKTS:PBSV CIK1304161 Webwww.pharmabioserv.com Phone(787) 278-2709Fax787-796-5168Employees185Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E Ratio4.36 P/E GrowthN/ANet Income-$780 thousand Net Margins-8.18% Pretax Margin-7.94% Return on Equity-5.61% Return on Assets-4.53% Debt Debt-to-Equity RatioN/A Current Ratio8.32 Quick Ratio8.32 Sales & Book Value Annual Sales$9.51 million Price / Sales1.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book0.80Miscellaneous Outstanding Shares22,932,000Free Float20,162,000Market Cap$11.01 million OptionableNot Optionable Beta0.64 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:PBSV) was last updated on 6/6/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredHow to target 627% gains from Trump’s tweetsPresident Trump is shaking up the market with his tweets and Truth Social posts... But while this chaos has...Monument Traders Alliance | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredTrump plotting new lockdown?It's listed inside the White House's own documents: Federal Register notice 90 FR 4544 to be exact. And wh...Porter & Company | SponsoredWhy hasn't Elon tweeted about this?Behind the scenes, there's an entirely different Tesla story brewing… . It's about a quiet stream of income...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharma-Bio Serv, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharma-Bio Serv With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.